BioMarin

Categoria:

U.S. Food and Drug Administration Approves BioMarin’s VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

P-BIO October 26, 2023Expanded Indication in the U.S. Now Includes Children of all ages with...

A Food and Drug Administration (FDA) aprova a terapia genética ROCTAVIAN™ para tratamento de hemofilia A severa

Imagem: Pixabay P-BIO 03 de julho de 2023 A BioMarin Pharmaceutical Inc., uma empresa biotecnológica global...